Contamination risk of 100% autologous serum eye drops in management of ocular surface diseases

Cornea

Volumn 32, Issue 8, 2013, Pages 1116-1119

  Thanathanee, Onsiri ^a   Phanphruk, Warachaya ^a   Anutarapongpan, Orapin ^a   Romphruk, Amornrat ^b   Suwan Apichon, Olan ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

autologous serum; infection; non preserved; sterility

Indexed keywords

EYE DROPS;

ADULT; AGED; ARTICLE; ASPERGILLUS; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL ARTICLE; DRUG CONTAMINATION; DRUG SAFETY; DRUG STERILITY; FOLLOW UP; FONSECAEA; FUNGUS CULTURE; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; MYCOSIS; OCULAR SURFACE DISEASE; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY;

ADULT; AGED; BACTERIA; CORNEAL DISEASES; DRUG CONTAMINATION; EYE INFECTIONS, BACTERIAL; EYE INFECTIONS, FUNGAL; FEMALE; FUNGI; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; SERUM;

EID: 84880573393     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3182910036     Document Type: Article

References (15)

1. Jeng BH. Use of autologous serum in the treatment of ocular surface disorders. Arch Ophthalmol. 2011;129:1610-1612.
2. Kojima T, Higuchi A, Goto E, et al. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008;27(suppl 1):S25-S30.
3. Lee GA, Chen SX. Autologous serum in the management of recalcitrant dry eye syndrome. Clin Experiment Ophthalmol. 2008;36:119-122.
4. Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. Arq Bras Oftalmol. 2008;71(suppl 6):47-54.
5. Ziakas NG, Boboridis KG, Terzidou C, et al. Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clin Experiment Ophthalmol. 2010;38:683-687.
6. Jover Botella A, Márquez Peiró JF, Márques K, et al. Effectiveness of 100% autologous serum drops in ocular surface disorders. Farm Hosp. 2011;35:8-13.
7. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467-1474.
8. Lagnado R, King AJ, Donald F, et al. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol. 2004;88:464-465.
9. Sauer R, Blüthner K, Seitz B. Sterility of non-preserved autologous serum drops for treatment of persistent corneal epithelial defects [in German]. Ophthalmologe. 2004;101:705-709.
10. Leite SC, de Castro RS, Alves M, et al. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2006;38:223-227.
11. Chakrabarti A, Singh R. The emerging epidemiology of mould infections in developing countries. Curr Opin Infect Dis. 2011;24:521-526.
12. Liu L, Hartwig D, Harloff S, et al. An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol. 2005;243:706-714.
13. Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorders. Int Ophthalmol Clin. 2000;40:113-122.
14. Poon AC, Geerling G, Dart JK, et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85:1188-1197.
15. Yamada C, King KE, Ness PM. Autologous serum eyedrops: literature review and implications for transfusion medicine specialists. Transfusion. 2008;48:1245-1255.